International Index of Erectile Function 5- items (IIEF-5)

Abstract

The International Index of Erectile Function 5-items (IIEF-5), also widely designated in clinical literature as the Sexual Health Inventory for Men (SHIM), is an abridged, self-administered psychometric instrument developed by Raymond C. Rosen and colleagues in 1999. Designed to optimize diagnostic efficiency in primary care, urology, and psychosexual research, the scale captures the presence and severity of erectile dysfunction (ED) over a six-month recall window. Derived from the multidimensional 15-item International Index of Erectile Function (IIEF-15), the IIEF-5 comprises five targeted items selected via rigorous statistical modeling, specifically discriminant analysis and factor reduction. These items assess erectile confidence, erection hardness sufficient for penetration, maintenance capability post-penetration, maintenance difficulty to completion of sexual intercourse, and overall intercourse satisfaction. Each item is rated on a 5-point ordinal scale (scores ranging from 1 to 5), yielding a composite score between 5 and 25 (with provisions for non-attempt classifications yielding scores down to 1 in diagnostic algorithms). Total scores are categorized into five clinically validated diagnostic bands: severe ED (1–7), moderate ED (8–11), mild-to-moderate ED (12–16), mild ED (17–21), and no ED (22–25). Extensive cross-cultural validation across North American, European, Asian, and Latin American cohorts has demonstrated high internal consistency (Cronbach’s alpha typically between .82 and .93), robust test-retest stability (intraclass correlation coefficients > .85), and superior diagnostic sensitivity (0.98) and specificity (0.88) at the clinical cutoff score of 21. Confirmatory factor analyses corroborate a robust unidimensional structure that reflects the physiological and subjective facets of erectile potency. The instrument is a gold-standard diagnostic and outcome measure in trials evaluating phosphodiesterase type 5 (PDE5) inhibitors, lifestyle modifications, and psychosexual interventions.

Keywords

IIEF-5, Sexual Health Inventory for Men, SHIM, erectile dysfunction, psychometrics, sexual medicine, penile rigidity, sexual satisfaction, psychosexual assessment, diagnostic accuracy

Authors

The IIEF-5 was formulated and validated by a multidisciplinary team of psychometricians, clinical psychologists, and clinical trialists led by:

• Raymond C. Rosen, Ph.D. — Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ), Piscataway, New Jersey, USA; and New England Research Institutes (NERI), Watertown, Massachusetts, USA.
• Joseph C. Cappelleri, Ph.D., M.P.H. — Global Research and Development, Pfizer Inc., Groton, Connecticut, USA (Lead Biostatistician and psychometric methodology specialist).
• Mark D. Smith, M.D. — Clinical Research Division, Pfizer Inc., New York, New York, USA.
• J. Lipsky, M.S. — Biostatistics and Clinical Informatics, Pfizer Inc., Groton, Connecticut, USA.
• B. M. Peña, M.D. — Medical Outcomes and Clinical Operations, Pfizer Inc., New York, New York, USA.

Inquiries regarding the theoretical development and psychometric modeling of the scale are historically directed to the primary research team through Pfizer Global Research or corresponding academic affiliates associated with Robert Wood Johnson Medical School.

Purpose

The clinical and psychometric imperative behind the creation of the IIEF-5 was to resolve the practical limitations of the original 15-item International Index of Erectile Function (IIEF). Although the IIEF-15 remains the benchmark comprehensive instrument for multidimensional sexual function research—spanning five distinct domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction—its administration length proved burdensome in routine outpatient consultations, large-scale epidemiologic surveys, and fast-paced primary care settings. Furthermore, clinicians required a standardized, unidimensional diagnostic threshold that could accurately discriminate between men with and without erectile dysfunction and reliably stratify severity.

The primary clinical purpose of the IIEF-5 is the rapid screening, diagnosis, and longitudinal staging of erectile dysfunction. Erectile dysfunction, defined by the National Institutes of Health (NIH) Consensus Development Panel as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, is a complex vascular, neurological, and psychogenic disorder. The IIEF-5 operates as a self-administered questionnaire that mitigates the shame, social desirability bias, and clinical communication barriers that frequently surround patient-physician dialogues regarding sexual dysfunction.

Beyond routine diagnosis, the purpose of the tool extends to:

• Therapeutic Monitoring: Serving as an objective, quantifiable endpoint in pharmacotherapy trials (e.g., sildenafil, tadalafil, vardenafil), surgical outcomes assessments (e.g., radical prostatectomy nerve-sparing evaluations, penile prosthesis implantation), and endocrinological therapies (e.g., testosterone replacement therapy).
• Epidemiological Surveillance: Facilitating community-based prevalence studies examining the association between male sexual health and underlying systemic pathologies, including cardiovascular disease, metabolic syndrome, peripheral neuropathy, and clinical depression.
• Biopsychosocial Staging: Differentiating between physiological failure of penile tumescence and psychological performance anxiety by evaluating both self-reported confidence and mechanical capacity during penetrative intercourse.

Psychological Construct

The IIEF-5 measures the psychophysiological construct of Erectile Function within an interactive biopsychosocial framework. Erectile competence is not solely a hemodynamic phenomenon of smooth muscle relaxation, arterial inflow, and veno-occlusion; it is inextricably intertwined with cognitive appraisal, partner intimacy, performance anxiety, and subjective sexual satisfaction.

The construct operationalized within the IIEF-5 integrates five interdependent components of male sexual performance:

• Erectile Self-Efficacy / Confidence (Item 1): Drawing upon principles of cognitive self-efficacy theory, this dimension assesses the individual’s subjective conviction and perceived agency regarding their physiological capacity to initiate and sustain an erection. Psychological expectancy directly influences autonomic nervous system tone; anticipatory performance anxiety elevates sympathetic outflow, releasing endogenous catecholamines that directly cause corporal vasoconstriction and detumescence.
• Penile Rigidity / Tumescence Sufficiency (Item 2): This facet evaluates the vascular and biomechanical capability of the penis to reach sufficient axial rigidity for vaginal or anal penetration under conditions of erotic stimulation. It serves as a behavioral marker of healthy neurovascular signaling and endothelial nitric oxide synthase (eNOS) activation.
• Post-Penetration Maintenance (Item 3): Capturing the duration and stability of the veno-occlusive mechanism following intromission, this dimension measures whether cavernous tissue can resist venous leakage during dynamic mechanical stimulation and sympathetic arousal shifts.
• Erection Maintenance Difficulty to Completion (Item 4): This item measures the subjective effort and psychological distress associated with sustaining tumescence through the entirety of the sexual act until climax. It reflects both physiological endurance and the cognitive interference caused by attentional distraction or self-monitoring (“spectatoring”).
• Intercourse Satisfaction (Item 5): Moving beyond physiological mechanics, this dimension integrates the affective, experiential, and evaluative component of the sexual encounter. Sexual satisfaction reflects whether the physiological event met personal and relational expectations, mitigating feelings of frustration, inadequacy, or distress.

Together, these items form a composite index where physiological functioning and psychological well-being operate in a continuous feedback loop: diminished physical rigidity fuels performance anxiety, which further degrades neurovascular performance, ultimately deteriorating overall sexual quality of life.

Theoretical Framework

The theoretical framework underpinning the IIEF-5 synthesizes Masters and Johnson’s human sexual response cycle, David H. Barlow’s cognitive-behavioral model of sexual dysfunction, and Bandura’s self-efficacy theory.

Under Masters and Johnson’s classical paradigm, male sexual response proceeds through excitement, plateau, orgasm, and resolution. Erectile dysfunction represents a primary disruption at the intersection of excitement and plateau. Rosen and colleagues recognized that purely mechanical conceptualizations failed to capture the subjective patient experience. Therefore, they integrated behavioral medicine principles to ensure that the patient’s own appraisal of erectile maintenance and personal satisfaction were mathematically weighted alongside mechanical rigidity.

Barlow’s cognitive-behavioral model provides the explanatory psychopathology: non-dysfunctional men exposed to sexual stimuli experience positive affect, focus attention on erotic cues, and undergo parasympathetic activation, resulting in penile tumescence. Conversely, men vulnerable to erectile dysfunction respond to sexual demands with negative affect and performance anxiety. They shift attention from erotic sensations toward internal threat monitoring (evaluative performance scrutiny, fear of failure). This hypervigilance activates the sympathetic nervous system, inducing alpha-adrenergic mediated vasoconstriction of the cavernous helicine arteries, precipitating physiological failure. The IIEF-5 mirrors this cyclical mechanism: Item 1 explicitly probes baseline cognitive confidence, Items 2 through 4 quantify physiological breakdown during execution, and Item 5 records the psychological evaluative outcome.

Furthermore, the instrument relies on psychometric item response theory and classical test theory, presuming that erectile dysfunction exists along a continuous severity spectrum. Rather than treating ED as a binary state (present vs. absent), the dimensional model assumes latent neurovascular and psychological impairment that gradually undermines functional stability.

Validity

The psychometric validity of the IIEF-5 has been comprehensively evaluated across clinical, community, and cross-cultural cohorts:

Criterion and Diagnostic Validity

In the original validation study by Rosen et al. (1999), the IIEF-5 demonstrated high diagnostic sensitivity and specificity. Receiver Operating Characteristic (ROC) curve analyses were conducted on a sample of 1,159 men with clinical ED and 456 control subjects without ED. An optimal cutoff score of 21 (out of 25) yielded:

• Sensitivity: 0.98 (98% of men with clinically confirmed ED scored 21 or below).
• Specificity: 0.88 (88% of men without ED scored 22 or above).
• Area Under the Curve (AUC): Reported at 0.96 to 0.98 across multiple validation cohorts, confirming exceptional diagnostic discriminative capacity.

Construct and Convergent Validity

Convergent validity is documented via strong positive correlations between the IIEF-5 and the full 15-item IIEF Erectile Function domain ($r > .90$, $p < .001$). Furthermore, the scale correlates robustly with objective physiological indices:

• Nocturnal Penile Tumescence and Rigidity (NPTR): Studies utilizing the RigiScan device have demonstrated significant correlations between IIEF-5 composite scores and nocturnal erectile duration, base rigidity, and tip rigidity ($r = .55$ to $.72$, $p < .01$).
• Penile Duplex Doppler Ultrasound: Lower IIEF-5 scores correlate strongly with hemodynamic abnormalities, such as diminished peak systolic velocity (PSV < 30 cm/s) indicative of arteriogenic ED, and elevated end-diastolic velocity (EDV > 5 cm/s) with a low resistive index indicative of veno-occlusive dysfunction.
• Psychological Inventories: Significant negative correlations have been established between IIEF-5 scores and measures of depression (e.g., Beck Depression Inventory, $r = -.38$ to $-.46$) and generalized anxiety (e.g., GAD-7, $r = -.34$).

Discriminant and Known-Groups Validity

Known-groups validation studies confirm that the IIEF-5 discriminates significantly between clinical sub-populations. Cohorts with established vascular risk factors (e.g., coronary artery disease, peripheral arterial disease, poorly controlled Type 2 diabetes mellitus) score significantly lower on the IIEF-5 than age-matched healthy controls ($p < .0001$). The instrument also effectively discriminates between post-radical prostatectomy patients undergoing bilateral nerve-sparing surgery versus non-nerve-sparing procedures.

Reliability

The IIEF-5 exhibits exceptional reliability across diverse languages and demographic populations:

Internal Consistency

Across the published psychometric literature, the Cronbach’s alpha coefficient for the five items ranges from .82 to .93:

• In the pioneering study by Rosen et al. (1999), Cronbach’s alpha was .91 in the clinical ED cohort and .86 in the control cohort.
• Subsequent multinational adaptations (including Italian, Spanish, German, Brazilian Portuguese, Turkish, Chinese, and Korean versions) have reported Cronbach’s alpha values consistently exceeding the accepted psychometric benchmark of .80, indicating high internal coherence among the five operational items.

Test-Retest Stability

Temporal stability evaluated over intervals ranging from two to four weeks in untreated, clinically stable cohorts yields intraclass correlation coefficients (ICC) and Pearson correlation coefficients ranging from $r = .84$ to $r = .92$ ($p < .001$). This confirms that the instrument possesses high reproducibility and is not subject to excessive random transient error, while remaining appropriately sensitive to therapeutic changes following pharmacological intervention.

Standard Error of Measurement and MCID

The Standard Error of Measurement (SEM) for the IIEF-5 is estimated between 1.1 and 1.6 points. Research evaluating the Minimal Clinically Important Difference (MCID)—the smallest improvement in score that a patient perceives as beneficial—indicates that a change of 2 to 5 points (depending on baseline severity: 2 points for mild, up to 5 points for severe baseline impairment) represents clinically meaningful therapeutic response.

Factor Analysis

The structural dimensionality of the IIEF-5 has been examined through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA).

Exploratory Factor Analysis

During the original item reduction process from the IIEF-15, principal component and factor analyses identified that items assessing erectile capacity, maintenance, and confidence loaded primarily onto a single dominant latent factor accounting for over 70% to 80% of the total variance. Factor loadings for each of the five items on this primary erectile competence dimension were exceptionally high:

• Item 1 (Confidence): Loading range: .73 – .81
• Item 2 (Penetration hardness): Loading range: .84 – .89
• Item 3 (Maintenance post-penetration): Loading range: .86 – .92
• Item 4 (Maintenance difficulty): Loading range: .83 – .90
• Item 5 (Intercourse satisfaction): Loading range: .71 – .82

Confirmatory Factor Analysis

Subsequent structural equation modeling across international validation cohorts has confirmed the adequacy of the unidimensional single-factor model. Confirmatory factor analytic indices consistently meet stringent psychometric criteria:

• Comparative Fit Index (CFI): > 0.96 to 0.99
• Tucker-Lewis Index (TLI): > 0.95 to 0.98
• Root Mean Square Error of Approximation (RMSEA): < 0.05 to 0.07
• Standardized Root Mean Square Residual (SRMR): < 0.03 to 0.04

Although Item 5 includes an evaluative satisfaction component, multi-group CFA models indicate that it loads strongly onto the general erectile potency factor without creating significant multidimensional disturbance, justifying the aggregation of all five items into a single composite score.

Instrument / Measurement Tool

• Instrument Name: International Index of Erectile Function 5-items (IIEF-5) / Sexual Health Inventory for Men (SHIM)
• Format: Paper-and-pencil questionnaire or validated digital self-report instrument
• Administration Time: Approximately 2 to 5 minutes
• Target Population: Adult men (18+ years) presenting for sexual health screening, urological evaluation, or clinical research
• Recall Period: Past 6 months
• Item Count: 5 items
• Response Format: 5-point Likert-type ordinal scale per item (scores 1 through 5). (Note: Clinical diagnostic coding allows a score of 0 when sexual activity or penetration was not attempted, though classical staging applies to active attempts scored 1–5).
• Scoring Mechanism: Direct summation of item response values. Scores range from 5 to 25 (or 1 to 25 when addressing non-attempts).
• Diagnostic Classification Thresholds:
  • Severe Erectile Dysfunction: 1 to 7
  • Moderate Erectile Dysfunction: 8 to 11
  • Mild-to-Moderate Erectile Dysfunction: 12 to 16
  • Mild Erectile Dysfunction: 17 to 21
  • No Erectile Dysfunction (Normal Function): 22 to 25

Permissions & Fee and Test Year

• Year of Publication: 1999 (Derived from the parent IIEF-15 published in 1997).
• Original Developers: Raymond C. Rosen, Joseph C. Cappelleri, Mark D. Smith, J. Lipsky, and B. M. Peña.
• Copyright & Intellectual Property: The original copyright is held by Pfizer Inc. and the authors. The IIEF and IIEF-5/SHIM instruments are protected intellectual property.
• Licensing and Usage Fees:
  • Academic & Non-Profit Research / Routine Clinical Care: The scale is widely available and typically permitted free of charge for individual clinical use, academic research, and non-commercial educational investigations, provided appropriate citation is given.
  • Commercial & Pharmaceutical Clinical Trials: Commercial use, pharmaceutical drug trials, funded industry studies, and digital health software integrations typically require formal licensing, translation certifications, and user fees managed through intellectual property distributors and outcomes measurement platforms (such as Mapi Research Trust / PROQOLID).

References

• Cappelleri, J. C., & Rosen, R. C. (2005). The Sexual Health Inventory for Men (IIEF-5): Utility in clinical practice and trials. International Journal of Impotence Research, 17(4), 307–319. https://doi.org/10.1038/sj.ijir.3901327
• National Institutes of Health. (1993). NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA: The Journal of the American Medical Association, 270(1), 83–90. https://doi.org/10.1001/jama.1993.03510010089036
• Rhoden, E. L., Telöken, C., Sogari, P. R., & Vargas, C. A. (2002). The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. International Journal of Impotence Research, 14(4), 245–250. https://doi.org/10.1038/sj.ijir.3900859
• Rosen, R. C., Althof, S. E., & Giuliano, F. (2006). Research instruments for the diagnosis and treatment of patients with erectile dysfunction. Urology, 68(3 Suppl), 6–16. https://doi.org/10.1016/j.urology.2006.05.044
• Rosen, R. C., Cappelleri, J. C., Smith, M. D., Lipsky, J., & Peña, B. M. (1999). Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. International Journal of Impotence Research, 11(6), 319–326. https://doi.org/10.1038/sj.ijir.3900472
• Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 49(6), 822–830. https://doi.org/10.1016/S0090-4295(97)00238-0

13. Items of the Scale (Questionnaire)